Skip to Content
Living with relapsing MS? Don’t miss these free events >>

Plegridy (peginterferon beta-1a) Disease Interactions

There are 9 disease interactions with Plegridy (peginterferon beta-1a):

Major

Interferons-Beta (Includes Plegridy) ↔ Hepatic Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons. In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury. The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs. Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.

Moderate

Peginterferon Beta-1A (Includes Plegridy) ↔ Autoimmune Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Autoimmune Disorder

Autoimmune disorders of multiple target organs including idiopathic thrombocytopenia, hyper- and hypothyroidism, and autoimmune hepatitis have been reported with interferon beta. If patients develop a new autoimmune disorder, consider stopping therapy with this agent. Care and close monitoring is recommended when prescribing this agent to patients at risk of developing an autoimmune disorder.

Moderate

Peginterferon Beta-1A (Includes Plegridy) ↔ Congestive Heart Failure

Moderate Potential Hazard, Moderate plausibility

Applies to: Heart Disease

Congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure occur in patients receiving interferon beta. It is recommended to monitor patients with significant cardiac disease for worsening of their cardiac condition during initiation and continuation of treatment.

Moderate

Peginterferon Beta-1A (Includes Plegridy) ↔ Decrease Blood Counts

Moderate Potential Hazard, Moderate plausibility

Applies to: Pancytopenia, Bone Marrow Depression/Low Blood Counts

Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia. It is recommended to monitor patients for infections, bleeding, and symptoms of anemia. Monitor complete blood cell counts, differential white blood cell counts, and platelet counts during treatment. Close monitoring is recommended when prescribing this agent to patients at risk, in particular to patients with myelosuppression.

Moderate

Peginterferon Beta-1A (Includes Plegridy) ↔ Depression

Moderate Potential Hazard, Moderate plausibility

Applies to: Depression

Depression, suicidal ideation, and suicide have been reported in patients receiving peginterferon beta. Patients should be monitored for any evidence of depression or other psychiatric symptoms. Patients should be advised to report any signs or symptoms of depression, or other changes in mood or behavior. In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.

Moderate

Peginterferon Beta-1A (Includes Plegridy) ↔ Injection Site Reaction

Moderate Potential Hazard, Moderate plausibility

Applies to: Dermatitis - Drug-Induced

Injection site reactions, including injection site necrosis, can occur with the use of subcutaneous interferon beta. Caution should be exercised when prescribing this agent and the decisions to discontinue therapy following necrosis at a single injection site should be based on the extent of the necrosis. For patients who continue therapy after injection site necrosis has occurred, it is recommended to avoid administration of this agent near the affected area until it is fully healed and if multiple lesions occur, discontinue therapy until healing occurs.

Moderate

Peginterferon Beta-1A (Includes Plegridy) ↔ Renal Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Pharmacokinetic studies have shown that renal impairment can increase the Cmax of Peginterferon beta-1a. Caution should be taken when prescribing this agent to these patients. It is recommended to monitor renal function, and to monitor for adverse reactions due to increased drug exposure in patients with severe renal impairment. Clinical monitoring of renal function is recommended.

Moderate

Peginterferon Beta-1A (Includes Plegridy) ↔ Seizures

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures

The use of peginterferon beta-1a may cause seizures. Exercise caution when prescribing this agent to patients with a history of seizure disorders. Close monitoring is recommended.

Moderate

Peginterferon Beta-1A (Includes Plegridy) ↔ Thrombotic Microangiopathy

Moderate Potential Hazard, Moderate plausibility

Applies to: Hemolytic Anemia, Vasculitis, Thrombocytopathy

Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products. Discontinue therapy if clinical symptoms and laboratory findings are consistent with TMA, and manage as clinically indicated. Care should be taken when prescribing this agent to patients at risk of endothelial injury.

Plegridy (peginterferon beta-1a) drug Interactions

There are 444 drug interactions with Plegridy (peginterferon beta-1a)

Plegridy (peginterferon beta-1a) alcohol/food Interactions

There is 1 alcohol/food interaction with Plegridy (peginterferon beta-1a)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide